FX.co ★ Entera Bio, OPKO Health Announce Positive Results For Oxyntomodulin Animal Models Against Obesity

Entera Bio Ltd. (ENTX) and Opko Health Inc. (OPK) announced encouraging pharmacokinetic and pharmacodynamic findings from their joint research on oral Oxyntomodulin (OXM) for combating obesity and metabolic disorders.

OXM, a naturally occurring peptide hormone present in the small intestine, helps suppress appetite and induce weight loss. It is being evaluated as a potential once-daily therapeutic solution for individuals suffering from obesity, metabolic dysfunctions, and fibrotic conditions.

In a proof of concept study conducted with rodent and pig models, oral OXM exhibited significant systemic exposure, a favorable pharmacokinetic profile, and promising bioavailability.

The research further showed that the administration of oral OXM resulted in a statistically significant reduction in plasma glucose levels following glucose administration, compared to a placebo, during a glucose tolerance test in rats.

"These bioavailability and pharmacological data bolster our efforts towards IND-enabling activities for this program," stated Miranda Toledano, CEO of Entera.

As of now, Entera's stock has declined by 3.06%, trading at $1.90 on the Nasdaq.